Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31424953 | 0.96 | PKM (0.57) | PKMCYP4F2CYP4A11TSHRSMN1; SMN2 | |
| SCHEMBL31424955 | 0.96 | PKM (0.57) | PKMCYP4F2CYP4A11TSHRSMN1; SMN2 | |
| SCHEMBL6878047 | 0.96 | PKM (0.57) | PKMCYP4F2CYP4A11TSHRSMN1; SMN2 | |
| SCHEMBL28362403 | 0.92 | PKM (0.54) | PKMCYP4F2CYP4A11TSHRSMN1; SMN2 | |
| SCHEMBL28670364 | 0.92 | PKM (0.54) | PKMCYP4F2CYP4A11TSHRSMN1; SMN2 | |
| SCHEMBL28392837 | 0.91 | PKM (0.53) | PKMCYP4F2CYP4A11TSHRSMN1; SMN2 | |
| SCHEMBL4671445 | 0.91 | PKM (0.53) | PKMCYP4F2CYP4A11TSHRSMN1; SMN2 | |
| SCHEMBL28362383 | 0.91 | PKM (0.53) | PKMCYP4F2CYP4A11TSHRSMN1; SMN2 | |
| SCHEMBL8851459 | 0.91 | PKM (0.53) | PKMCYP4F2CYP4A11TSHRSMN1; SMN2 | |
| SCHEMBL1107140 | 0.90 | PKM (0.55) | PKMCYP4F2CYP4A11TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103951812-A | Preparation method of epoxy polyamide type paper making wet strength agent | ZHEJIANG TRANSFAR WHYYON CHEMICAL CO LTD | 2014-07-30 | — | — | CN | claimed |
| EP-3541812-B1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-06-14 | — | — | EP | disclosed |
| EP-3541812-B1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-06-14 | — | — | EP | disclosed |
| US-11465994-B2 | MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-11 | — | — | US | disclosed |
| CN-113549010-A | Preparation and application of compound with AMPK agonistic activity and prodrug thereof | 中国科学院上海药物研究所 | 2021-10-26 | — | — | CN | disclosed |
| US-10654858-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190345148-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-11-14 | — | — | US | disclosed |
| US-20190345148-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-11-14 | — | — | US | disclosed |
| EP-3541812-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | Takeda Pharmaceutical Company Limited (JP) | 2019-09-25 | — | — | EP | disclosed |
| US-20190211019-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2019-07-11 | — | — | US | disclosed |
| US-20110207757-A1 | Tricyclic Compounds Having Cytostatic and/or Cytoxic Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2011-08-25 | — | — | US | disclosed |
| US-7960400-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960400-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960400-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110092662-A1 | AROMATIC POLYESTER | NITTA CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2200437-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | Duquesne University of the Holy Ghost (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090062318-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2009-03-05 | — | — | US | disclosed |
| US-20090062318-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2009-03-05 | — | — | US | disclosed |
| US-20090062318-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2009-03-05 | — | — | US | disclosed |
| WO-2009029473-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11465994-B2 | MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions | GRM7, GRM2, GRM1 | PKM 1945/4885CYP4F2 2234/4885CYP4A11 2083/4885 |
| US-20090062318-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DHFR, TK1, TYMS | PKM 1078/4885CYP4F2 1457/4885CYP4A11 2671/4885 |
| US-20190211019-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DHFR, TK1, TYMS | PKM 1078/4885CYP4F2 1457/4885CYP4A11 2671/4885 |
| US-20190345148-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS | GRM7, GRM2, GRM1 | PKM 1945/4885CYP4F2 2234/4885CYP4A11 2083/4885 |
| US-20110207757-A1 | Tricyclic Compounds Having Cytostatic and/or Cytoxic Activity and Methods of Use Thereof | DHFR, TK1, TK2 | PKM 1250/4885CYP4F2 1330/4885CYP4A11 2558/4885 |
| US-10654858-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DHFR, TK1, TYMS | PKM 1078/4885CYP4F2 1457/4885CYP4A11 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.